Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022867 | 0.83 | KCNH2 (0.54) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL4358403 | 0.81 | KCNH2 (0.66) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4209774 | 0.78 | L3MBTL1 (0.48) | KCNH2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL5003301 | 0.76 | KCNH2 (0.53) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6379406 | 0.75 | HSD17B10 (0.38) | KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4206093 | 0.75 | KCNH2 (0.71) | KCNH2 | |
| SCHEMBL4216135 | 0.75 | KCNH2 (0.71) | KCNH2 | |
| SCHEMBL9655108 | 0.70 | ADRB2 (0.56) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4196753 | 0.69 | ALDH1A1 (0.58) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10827925 | 0.69 | KDM4E (0.41) | CYP1A2CYP3A4CYP2D6CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | claimed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | claimed |
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | GRIN1, GRIA4, GRIA1 | KCNH2 287/4885CYP1A2 4160/4885CYP3A4 1940/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | KCNH2 382/4885CYP1A2 4425/4885CYP3A4 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.